Insider Trading Alert - CARA, GCAP And FMER Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 5, 2015, 84 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $500.00 to $1,572,413.89.

Highlighted Stocks Traded by Insiders:

Cara Therapeutics (CARA) - FREE Research Report

Lewis Michael E, who is Chief Scientific Advisor at Cara Therapeutics, sold 7,262 shares at $10.64 on May 5, 2015. Following this transaction, the Chief Scientific Advisor owned 336,774 shares meaning that the stake was reduced by 2.11% with the 7,262-share transaction.

The shares most recently traded at $10.15, down $0.49, or 4.83% since the insider transaction. Historical insider transactions for Cara Therapeutics go as follows:

  • 4-Week # shares sold: 7,262
  • 12-Week # shares sold: 29,524
  • 24-Week # shares sold: 36,786

The average volume for Cara Therapeutics has been 187,800 shares per day over the past 30 days. Cara Therapeutics has a market cap of $238.7 million and is part of the health care sector and drugs industry. Shares are up 4.91% year-to-date as of the close of trading on Tuesday.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Currently, there are 4 analysts who rate Cara Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CARA - FREE

TheStreet Quant Ratings rates Cara Therapeutics as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and notable return on equity. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and deteriorating net income. Get the full Cara Therapeutics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

GAIN Capital Holdings (GCAP) - FREE Research Report

Calhoun Christopher Warren, who is Director at GAIN Capital Holdings, sold 12,500 shares at $10.18 on May 5, 2015. Following this transaction, the Director owned 40,291 shares meaning that the stake was reduced by 23.68% with the 12,500-share transaction.

The shares most recently traded at $9.53, down $0.65, or 6.8% since the insider transaction. Historical insider transactions for GAIN Capital Holdings go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 32,997
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 152,548
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 209,548

The average volume for GAIN Capital Holdings has been 256,400 shares per day over the past 30 days. GAIN Capital Holdings has a market cap of $447.8 million and is part of the financial sector and financial services industry. Shares are up 14.41% year-to-date as of the close of trading on Tuesday.

GAIN Capital Holdings, Inc. provides trading services and solutions to retail and institutional customers worldwide. The stock currently has a dividend yield of 1.94%. The company has a P/E ratio of 14.5. Currently, there are 2 analysts who rate GAIN Capital Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GCAP - FREE

TheStreet Quant Ratings rates GAIN Capital Holdings as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full GAIN Capital Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Firstmerit (FMER) - FREE Research Report

Strobel Russ M, who is Director at Firstmerit, bought 2,000 shares at $19.20 on May 5, 2015. Following this transaction, the Director owned 21,143 shares meaning that the stake was boosted by 10.45% with the 2,000-share transaction.

The shares most recently traded at $19.36, up $0.16, or 0.83% since the insider transaction. Historical insider transactions for Firstmerit go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 11,004
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 11,004
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 16,998

The average volume for Firstmerit has been 852,600 shares per day over the past 30 days. Firstmerit has a market cap of $3.2 billion and is part of the financial sector and banking industry. Shares are up 1.85% year-to-date as of the close of trading on Tuesday.

FirstMerit Corporation operates as the bank holding company for FirstMerit Bank N.A. that provides various banking, fiduciary, financial, insurance, and investment services to corporate, institutional, and individual customers. The stock currently has a dividend yield of 3.33%. The company has a P/E ratio of 13.7. Currently, there are 3 analysts who rate Firstmerit a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FMER - FREE

TheStreet Quant Ratings rates Firstmerit as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, expanding profit margins, attractive valuation levels and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Firstmerit Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Tesla Jumps on Model 3 Expansion Hopes, China Trade Truce

Tesla Jumps on Model 3 Expansion Hopes, China Trade Truce

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO